In-Depth Guide
The Economics of GLP-1 Weight Loss Drugs
GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, Zepbound — have become the most commercially significant drug class since statins. Clinical trials show 15–20% average body weight loss, meaningful cardiovascular risk reduction, and demonstrated benefits for conditions ranging from sleep apnea to kidney disease. They have also created one of the sharpest access-versus-cost divides in modern medicine.
The Out-of-Pocket Reality
Without insurance, a month's supply of Wegovy costs approximately $1,100–$1,350 as of May 2026. Ozempic, the diabetes formulation of the same active ingredient, runs $1,000–$1,200 per month. Annualized, that is $12,000–$16,200 per year before factoring in prescriber visits and lab work. The insurance picture is better but inconsistent. Most commercial plans cover Ozempic for type 2 diabetes. Wegovy coverage for weight loss is improving, with Medicare now covering it for patients with qualifying cardiovascular risk. With coverage, most patients pay $25–$75 per month.
What the Savings Calculation Shows
Obesity-related medical costs are substantial and well-documented. Conditions improved or resolved by significant weight loss include type 2 diabetes, hypertension, obstructive sleep apnea, elevated cholesterol, and acid reflux. Published clinical studies show average annual medical cost savings of $1,800–$2,400 per 10% of body weight lost. For a 240-pound person who loses 15%, that is potentially $2,700–$3,600 per year in reduced medical spending — medication changes, fewer specialist visits, lower lab costs. The calculator models how these savings offset drug costs over time.
The Long-Term Commitment
Most patients regain weight when they stop the medication — this is documented across multiple randomized trials. GLP-1 drugs appear to work by altering appetite signaling in ways that require continuous treatment to maintain results. The realistic planning assumption is not "I will take this for a year" but rather "this is likely a long-term medication, similar to a blood pressure drug." That changes the five-year and ten-year cost calculations considerably, and it is a conversation worth having with your prescriber before starting.
The Compounding Situation
As of May 2026, compounded semaglutide is largely unavailable through legitimate channels. The FDA removed the drug shortage designation in February 2025, which eliminated the legal basis for routine compounding under shortage exemptions. In April 2026, the FDA proposed permanently barring large-scale 503B outsourcing facilities from producing compounded semaglutide. Some 503A patient-specific pharmacies continue operating in legal gray areas, but availability is diminishing and the regulatory direction is clear. Patients who relied on compounded versions at $99–$299 per month are facing a significant transition.
Making the Decision
The core question this calculator helps answer is whether the math makes sense for your situation. For patients with significant weight-related comorbidities, the net cost after medical savings can be substantially lower than the sticker price suggests. For patients without comorbidities who are primarily seeking cosmetic weight loss, the economic case is harder. Use the output as a financial framework, not a medical recommendation — the clinical decision belongs with your healthcare provider.